Click here to return to main plasmids page
|
|
|
| |||
|
|
| ||||
| Paper Name | Reference | Lab Name | Distribute? | Resistance | Notes |
GFP | [1] | pCIneoEGFP | amp | GFP in Promega pCIneo (uses CMV promoter). Superior to pfwB for some purposes | ||
| [1] | pCDNAf | yes | amp | GFP in Invitrogen pCDNA3.1 | |
| [2] | pfwB | blast or zeo | GFP under control of EF1alpha promoter. Titer yield somewhat better than pYafw. No PV sequences. | ||
| [3] | p8fwB | yes | blast or zeo | 8 kb. IFN-ß SAR stuffer DNA is compatible with packaging | |
|
| pEGFP-N1 | Clontech | kan | Small enough to package in polyomavirus-based reporter vectors | |
| [4-6] | pYafw | yes | blast | GFP under control of EF1alpha promoter. Small enough for PyVs | |
|
|
|
|
|
|
|
RFP | [7] | p8RwB | yes | blast or zeo | dsRed-Express (Clontech) 8kb plasmid | |
| [8] | pRwB | yes | blast or zeo | dsRed-Express (Clontech). Smaller (5.8kb) variant of p8RwB. | |
| ptwB | yes, Tsien MTA | blast or zeo | |||
| [10] | pCIR | yes | amp | dsRed-Express in pCIneo | |
|
|
|
|
|
|
|
SEAP | [11] | pYSEAP | blast |
| ||
|
|
|
|
|
|
|
Luciferase | [8] | pCLucf | amp | Firefly Luciferase under control of CMV promoter. Also encodes GFP under control of SV40 promoter. | ||
| [12] | phGluc | no* | zeo | Gaussia luciferase (secreted) under control of EF1alpha promoter. Suitable size for polyomavirus-based vectors | |
| [6] | pCGluc | no* | zeo | Gaussia luciferase (secreted) under control of CMV promoter. Suitable size for polyomavirus-based vectors | |
| [13] | phsNuc | ask | zeo | NanoLuc expression under control of EF1α promoter. Packageable. | |
| [13] | pcsNuc | ask | kan | NanoLuc expression under control of CMV promoter. Packageable. | |
| [13] | pH2BN | ask | zeo | Histone H2B fused to NanoLuc – used to produce NanoLuc VLPs | |
|
|
|
|
|
|
|
CD4 | [14] | pNaMB | yes | blast | This plasmid encodes tailless human CD4 (Miltenyi) | |
|
|
|
|
|
|
|
Vaccine Antigen | [10] | pCMMf | yes | amp | RSV M-M2 fusion protein expression plasmid for vaccine studies. SV40-GFP cassette in backbone for titering | |
| [15] | pCRSVF(a)cmF (mod) | yes | amp | RSV F protein expression plasmid for vaccine studies. SV40-GFP cassette in backbone for titering | |
.
*This plasmid contains a Gaussia luciferase gene licensed through purchase of pCMV-GLucfrom NEB. The license prevents us from distributing phGluc.
In our hands, Promega’s new NanoLuc reporter has proven to be superior to Gaussia luciferase for many applications.
1. Buck, C.B. and C.D. Thompson, Production of papillomavirus-based gene transfer vectors.Curr Protoc Cell Biol, 2007. Chapter 26: p. Unit 26.1.
2. Buck, C.B., et al., Maturation of papillomavirus capsids.J Virol, 2005. 79(5): p. 2839-46.
3. Buck, C.B., et al., Human alpha-defensins block papillomavirus infection.Proc Natl Acad Sci U S A, 2006. 103(5): p. 1516-21.
4. Buck, C.B., et al., Efficient intracellular assembly of papillomaviral vectors.J Virol, 2004. 78(2): p. 751-7.
5. Schowalter, R.M., W.C. Reinhold, and C.B. Buck, Entry tropism of BK and Merkel Cell Polyomaviruses in cell culture.PLoS One, 2012. 7(7): p. e42181.
6. Schowalter, R.M. and C.B. Buck, The Merkel cell polyomavirus minor capsid protein.PLoS Pathog, 2013. 9(8): p. e1003558.
7. Roberts, J.N., et al., Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.Nat Med, 2007. 13(7): p. 857-61.
8. Johnson, K.M., et al., Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.J Virol, 2009. 83(5): p. 2067-74.
9. Shaner, N.C., et al., Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein.Nat Biotechnol, 2004. 22(12): p. 1567-72.
10. Graham, B.S., et al., Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.Mucosal Immunol, 2010. 3(5): p. 475-86.
11. Pastrana, D.V., et al., Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.Virology, 2004. 321(2): p. 205-16.
12. Pastrana, D.V., et al., Quantitation of human seroresponsiveness to Merkel cell polyomavirus.PLoS Pathog, 2009.5(9): p. e1000578.
13. Geoghegan, E.M., et al., Infectious Entry and Neutralization of Pathogenic JC Polyomaviruses.Cell Rep, 2017. 21(5): p. 1169-1179.
14. Handisurya, A., et al., Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species.Virology, 2012. 433(2): p. 385-94.
15. Kines, R.C., et al., Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.PLoS One, 2015. 10(3): p. e0120797.